Actavis Inc. June 5 confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration for a generic version of Bayer’s birth control drug Safyral.
Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) is indicated to prevent pregnancy in women who elect to use an oral contraceptive, and to provide a daily dose of folate supplementation.
Merck & Co., Bayer Pharma AG, and Bayer Healthcare Pharmaceuticals Inc. filed suit against Actavis June 4 in the U.S. District Court of Delaware, seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.